News Voyageur Pharmaceuticals Ltd. Toronto S.E.

Stocks

VM

CA92916K1057

Pharmaceuticals

Delayed Toronto S.E.			5-day change	1st Jan Change
- ^CAD	-.--%		+7.14%	-

10-02	Voyageur Pharmaceuticals Settles CA$192,300 Debt by Issuing Shares	MT
09-25	Voyageur Pharmaceuticals to Issue Shares to Settle Debt of CA$192,300	MT

All News

Mentions Relevance

10-02	Voyageur Pharmaceuticals Announces Completion of Shares for Debt Settlement	NE
09-24	Voyageur Pharmaceuticals Announces Proposed Issuance of Shares for Debt	NE
09-10	(PODCAST) Voyageur Pharmaceuticals (TSXV:VM) Achieves First Milestone in Bayer Collaboration, Secures USD $1 Million Payment	AQ
09-09	Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment	AQ
08-10	Voyageur Pharmaceuticals Ltd. Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing	CI
08-10	Voyageur Pharmaceuticals Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing	AQ
07-24	Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2026	CI
07-17	Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker	NE
06-23	Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility	AQ
06-18	Voyageur Pharmaceuticals Evaluates Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility	CI
06-18	Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and High-Skilled Jobs; Competitive Site Selection Process Underway	AQ
06-10	Voyageur Pharmaceuticals Ltd Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support At Frances Creek Barite Project	CI
06-10	Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project	AQ
06-05	Voyageur Announces Closing Of Non-Brokered Private Placement Pursuant To Listed Issuer Financing Exemption	AQ
06-04	Voyageur Pharmaceuticals Ltd. announced that it has received CAD 5.005278 million in funding	CI
04-30	Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 10 million in funding	CI
04-30	Voyageur Pharmaceuticals Ltd. cancelled the transaction announced on March 24, 2026	CI
04-24	Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 28, 2026	CI
04-17	Voyageur Announces Shares for Debt Settlement and Stock Option Repricing	AQ
03-27	Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended November 30, 2025	CI
03-26	Voyageur Pharmaceuticals Ltd. Auditor Raises 'Going Concern' Doubt	CI
03-23	Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 7.5 million in funding	CI
03-16	Voyageur Announces Advancements on its Barium & Iodine Contrast Media Projects	AQ
03-05	Voyageur Pharmaceuticals : Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant	PU
03-04	Voyageur Pharmaceuticals Ltd. Announces Independent Laboratory Test Results for Its Barium Sulfate Active Pharmaceutical Ingredient	CI